<DOC>
	<DOC>NCT01363557</DOC>
	<brief_summary>Multicentre randomised (1:1) trial assessing the efficacy of whole brain radiotherapy in addition to Gefitinib for the management of brain metastasis in lung cancer patients with a mutated EGFR.</brief_summary>
	<brief_title>Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis</brief_title>
	<detailed_description>Lung cancer patients with newly diagnosed CNS metastasis with- at least one brain lesion measuring &gt; 1 cm in longest dimension - not eligible for surgery or stereotactic radio-surgeryOpen-label, multicentre, national, randomised (1:1) phase II trialArm A: WBRT and Concurrent Gefitinib followed by Gefitinib Maintenance Arm B: Gefitinib</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms, Second Primary</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Patients must have signed a written informed consent form prior to any study specific screening procedures 18 years or older KPS ≥ 50% Histologically confirmed adenocarcinoma of the lung Activating mutation of EGFR Newly diagnosed CNS metastasis or in progression with at least one measurable lesion in the brain (defined as any lesion &gt; 1 cm on T1weighted contrast enhanced MRI) Patients could enter the study regardless of previous treatment (included chemotherapy) for metastatic extracranial disease, except TKI. No steroids or stable or decreasing dose of steroids for at least 5 days before the MRI evaluation. Adequate hematologic, liver and renal functions: neutrophil count ≥ 1.5 x 109/L; platelets ≥ 100 x 109/L; Hb ≥ 9 g/Dl; Total bilirubin &lt; 1.5 x ULN; AST or ALT &lt; 2.5 x ULN (&lt; 5 x ULN in patients with liver metastases); Serum creatinine ≤ 1.5 x ULN or Creatinine clearance ≥ 50 mL/min Prior treatment of brain metastases with WBRT or TKI Patient eligible for radiosurgery or surgical resection Contre indication at the radiotherapy Leptomeningeal disease Previous history of cancer (other than curatively treated basal and squamous cell carcinoma of the skin and/or insitu carcinoma of the cervix) within the the 5 years before study entry Prior treatment with Gefitinib or other TKI Pregnant or breast feeding women Women with an intact uterus (unless amenorrhoeic for the last 24 months) not using effective means of contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Randomized</keyword>
	<keyword>Brain Radiation Therapy</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Brain Metastasis</keyword>
	<keyword>Gefitinib</keyword>
</DOC>